Haleon Pakistan Ltd
Haleon Pakistan Ltd operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of healthcare products.
Business. Haleon Pakistan Ltd (HALE.PSX) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm is headquartered in Pakistan and is primarily listed on the Pakistan Stock Exchange. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a product-sale entity within the pharmaceuticals industry.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Haleon Pakistan Ltd (HALE.PSX) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm is headquartered in Pakistan and is primarily listed on the Pakistan Stock Exchange. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a product-sale entity within the pharmaceuticals industry.
Haleon Pakistan Ltd maintains a strong liquidity position, with a current ratio of 1.36, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its operating cash flow of PKR 3.25 billion and free cash flow of PKR 1.04 billion. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity challenge in the near term.
In terms of profitability, Haleon Pakistan Ltd demonstrates a return on equity (ROE) of 12.36% and a return on assets (ROA) of 5.54%. These figures suggest the company is generating reasonable returns for its shareholders and effectively utilizing its assets. The company's operating income of PKR 2.09 billion and net income of PKR 1.22 billion further support its profitability. The debt-to-equity ratio of 0.02 indicates a conservative capital structure with minimal leverage.
Geographically, Haleon Pakistan Ltd is primarily focused on the domestic market, with no disclosed international revenue segments. The company's revenue concentration in Pakistan may expose it to local economic and regulatory risks. The company's business is not segmented by product lines in the provided data, but its primary activity is in pharmaceuticals and medical research.
Looking at the growth trajectory, the company's revenue for the latest period was PKR 9.81 billion. While the outlook for the current and next fiscal years is not explicitly provided, the company's capital expenditure of PKR -1.09 billion suggests a focus on cost management rather than expansion. The company's free cash flow of PKR 1.04 billion indicates it has the financial flexibility to support operations and potentially fund future growth initiatives.
The risk assessment for Haleon Pakistan Ltd highlights a medium liquidity risk and a low dilution risk. The company's dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. The company's conservative capital structure and strong cash flow position it to manage its debt obligations effectively. However, the negative net cash position after subtracting total debt is a concern that may require monitoring.
Recent events and filings for Haleon Pakistan Ltd do not include specific details in the provided data. Analyst estimates suggest a mean price target of PKR 1,134.00, with a median price target of PKR 1,134.00 and a recommendation mean of 2.50, indicating a neutral outlook. The company has one buy and one hold recommendation, with no strong buy recommendations.
- Haleon Pakistan Ltd has a strong liquidity position with a current ratio of 1.36 and positive operating and free cash flows.
- The company's ROE of 12.36% and ROA of 5.54% indicate solid profitability and efficient asset utilization.
- The company's revenue is concentrated in Pakistan, which may expose it to local economic and regulatory risks.
- The company's capital expenditure is negative, suggesting a focus on cost management rather than expansion.
- The company has a low dilution risk, with no significant changes in shares outstanding.
- Analysts have a neutral outlook on the company, with a mean price target of PKR 1,134.00.
Bull / Bear case
Generated · model-assistedAnalysts project 52% upside to a mean price target of 1,134 PKR, signaling strong institutional confidence in future performance.
Net income surged 359.9% year-over-year to 6.37 billion PKR, reflecting robust profitability recovery and strong bottom-line growth.
Debt-to-equity ratio of 0.02 is well below the cohort median of 0.18, highlighting a conservative and resilient capital structure.
Revenue CAGR of -3.6% over four years indicates a long-term decline in top-line growth despite recent recovery.
Net income CAGR of -7.9% over four years suggests underlying earnings volatility and inconsistent long-term profitability trends.
Medium liquidity risk flags potential challenges in trading volume or market depth, which could impact price stability.
Free cash flow remains volatile, dropping to 1.48 billion PKR from 1.81 billion PKR in the earliest period.
In focus — financials by report
Revenue PKR 43.11B, +15,9% YoY; Operating income +38,5% YoY.
- ▍Revenue PKR 43.11B, +15,9% YoY
- ▍Operating income +38,5% YoY
- ▍Net income +39,2% YoY
- ▍Free cash flow +1 041,5% YoY
- ▍Net margin 14.8%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 63,30 |
| Revenue | —no estimate | —no estimate | 50,3B PKR |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Haleon Pakistan Ltd Market data — financials · 2026-05-28
- Haleon Pakistan Ltd Market data — analyst estimates · 2026-05-28
Ownership & reference
Leadership
- Farhan Muhammad HaroonChief Executive Officer, Executive Director